The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - Dalton transactions, 2010 - pubs.rsc.org
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
The status of platinum anticancer drugs in the clinic and in clinical trials.
NJ Wheate, S Walker, GE Craig… - … Cambridge, England: 2003 …, 2010 - europepmc.org
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
[PDF][PDF] The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - Dalton Trans, 2010 - scholar.archive.org
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
[PDF][PDF] The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - Dalton Trans, 2010 - researchgate.net
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig… - Dalton transactions …, 2010 - pubmed.ncbi.nlm.nih.gov
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - 2010 - ses.library.usyd.edu.au
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
[引用][C] The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - Dalton Transactions, 2010 - cir.nii.ac.jp
[PDF][PDF] The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - Dalton Trans, 2010 - academia.edu
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
The status of platinum anticancer drugs in the clinic and in clinical trials
NJ Wheate, S Walker, GE Craig, R Oun - 2010 - ses.library.usyd.edu.au
Since its approval in 1979 cisplatin has become an important component in chemotherapy
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …
regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as …